개체 변이가 큰 약물 (highly variable drug)의 생물학적동등성 시험을 위한 실험설계 및 평가방법
Bioequivalence Approaches for Highly Variable Drugs: Issue and Solution
1
조회
0
다운로드
4
인용
0
참고문헌
키워드
초록
Highly variable drugs (within-subject variability greater than 30%) have been difficult to meet current regulatory acceptance criteria using a reasonable number of study subjects. In this study, we reviewed previous studies presenting alternative approaches for bioequivalence evaluation of highly variable drugs, and focused on an approach for widening the bioequivalence acceptance limits using within-subject variability. We discussed the suggested five solutions for highly variable drug including the deletion of Cmax of the bioequivalence criteria, direct expansion of bioequivalence limit, multiple dose studies in steady state, bioequivalence assessment on the metabolite, add-on study, and widening the bioequivalence acceptance limits based on reference variability. The methods for widening of bioequivalence limits based on reference variability are scaled average bioequivalence containing within-subject variability on reference drug (σWR), population bioequivalence derived from total variability on reference drug (σTR) and test drug (σTT), and individual bioequivalence derived from subject by formulation interaction variability (σD) and within subject variability on reference drug (σWR) and test drug (σTR). To apply these methods, the switching variability (σ0) will have to be set by the regulatory authorities. The proposals of bioequivalence evaluation approach for the highly variable in Korea are presented for both of new drug and reevaluation drug.
Abstract
Highly variable drugs (within-subject variability greater than 30%) have been difficult to meet current regulatory acceptance criteria using a reasonable number of study subjects. In this study, we reviewed previous studies presenting alternative approaches for bioequivalence evaluation of highly variable drugs, and focused on an approach for widening the bioequivalence acceptance limits using within-subject variability. We discussed the suggested five solutions for highly variable drug including the deletion of Cmax of the bioequivalence criteria, direct expansion of bioequivalence limit, multiple dose studies in steady state, bioequivalence assessment on the metabolite, add-on study, and widening the bioequivalence acceptance limits based on reference variability. The methods for widening of bioequivalence limits based on reference variability are scaled average bioequivalence containing within-subject variability on reference drug (σWR), population bioequivalence derived from total variability on reference drug (σTR) and test drug (σTT), and individual bioequivalence derived from subject by formulation interaction variability (σD) and within subject variability on reference drug (σWR) and test drug (σTR). To apply these methods, the switching variability (σ0) will have to be set by the regulatory authorities. The proposals of bioequivalence evaluation approach for the highly variable in Korea are presented for both of new drug and reevaluation drug.
참고문헌 (39)
- 식품의약품안전청, "생물학적동등성시험 기준 (고시 제2008-22호). 식품의약품안전청", ~ (2008)
- Hauschke D, "A distribution-free procedure for the statistical analysis of bioequivalence studies", Int J Clin Pharmacol Ther Toxicol, 28, pp.72~78 (1990)
- Schulz HU, "Striving for standards in bioequivalence assessment: a review", Int J Clin Pharmacol Ther Toxicol, 30, pp.S1~S6 (1992)
- The National Institute of Health Sciences, "Guideline for Bioequivalence Studies of Generic Product" (1997), The National Institute of Health Sciences
- The U.S. Food and Drug Administration, "Guidance for industry: bioavailability and bioequivalence studies for orally administered drug products- general considerations" (2003), The U.S. Food and Drug Administration
- The U.S. Food and Drug Administration, "Guidance for industry: statistical Approaches Establishing Bioequivalence" (2001), The U.S. Food and Drug Administration
- The Committee for Medicinal Products for Human Use, "Guidance on the Investigation of Bioequivalence" (2008), The European Medicines Agency
- Health Canada, "Guidance for Industry, Conduct and Analysis of Bioavailability and Bioequivalence Studies-Part A" (1992), Minister of Public Works and Government Services Canada
- Blume HH, "Bio-international ’92 Conference on Bioavailability, Bioequivalence and Pharmacokinetic Studies", Pharm Res, 10, pp.1806~1811 (1993)
- Haidar SH, "Bioequivalence approaches for highly variable drugs and drugs products", Pharm Res, 25(1), pp.237~241 (2008)
- Tothfalusi L, "Evaluation of the bioequivalence of highly-variable drugs and drug products", Pharm Res, 18(6), pp.728~733 (2001)
- Boddy AW, "An approach for widening the bioequivalence acceptance limits in the case of highly variable drugs", Pharm Res, 12, pp.1865~1868 (1995)
- Health Canada, "Bioequivalence requirements - highly variable drugs and highly variable drug products: issues and options", Expert Advisory Committee on Bioavailability and Bioequivalence (EAC-BB) Meeting, pp.26~27 (2003)
- Buice RG, "Bioequivalence of a highly variable drug: an experience with nadolol", Pharm Res, 13(7), pp.1109~1115 (1996)
- Davit BM, "Highly Variable Drugs: Observations from Bioequivalence Data Submitted to the FDA for New Generic Drug Applications", The AAPS Journal, 10(1), pp.148~156 (2008)
- Salmon S, "Statistical design and evaluation of bioequivalence studies average bioequivalence", WHO Prequalification program workshop, pp.25~27 (2007)
- Tothfalusi L, "Evaluation of some properties of individual bioequivalence (IBE) from replicate-design studies", Int J Clin Pharmacol Ther, 39(4), pp.162~166 (2001)
- Welling PG, "Factors contributing to variability in drug pharmacokinetics. I. Absorption", J Clin Hosp Pharm, 9(3), pp.163~179 (1984)
- Routledge PA, "Factors contributing to variability in drug pharmacokinetics. II. Drug distribution", J Clin Hosp Pharm, 10(1), pp.15~23 (1985)
- Jack DB, "Factors contributing to variability in drug pharmacokinetics. III. Metabolism", J Clin Hosp Pharm, 10(1), pp.25~43 (1985)
- Regårdh CG, "Factors contributing to variability in drug pharmacokinetics. IV. Renal excretion", J Clin Hosp Pharm, 10(4), pp.337~349 (1985)
- Midha KK, "Conference report:Bio-International 2005", J Pharm Sci, 96(4), pp.747~754 (2007)
- Patnaik R, "Highly Variable Drugs and Drug Products: A Rationale for Solution of a Persistent Problem", AAPS Workshop on BE, BCS and Beyond, Bethesda (2007)
- Schuirmann DJ, "A comparison of the two one-sided tests procedure and the power approach for assessing the equivalence of average bioavailability", J. Pharmacokinet. Biopharm, 15, pp.657~680 (1987)
- Patterson SD, "Nontraditional study designs to demonstrate average bioequivalence for highly variable drug products", Eur J Clin Pharmacol, 57(9), pp.663~670 (2001)
- García-Arieta A, "Highly Variable Drugs" (2006), Understanding Bioequivalence of Generic Drugs, A Worldwide Review
- "highly variable drugs-bioequivalence issues: FDA proposal under consideration"[URL]
- Haidar SH, "Evaluation of a scaling approach for highly variable drugs" (2006), Advisory Committee for Pharmaceutical Science
- Paul Fackler, "Bioequivalence for highly variable drugs:session III", pp.11~15 (2007), American Association of Pharmaceutical Scientists
- Committee for medicinal products for human use, "Concept paper for an addendum to the note for guidance on the investigation of bioavailability and bioequivalence: evaluation of bioequivalence of highly variable drugs and drug products" (2006), European Medicines Agency
- Hauck WW, "Limits of 80%-125% for AUC and 70%-143% for Cmax. What is the impact on bioequivalence studies?", Int J Clin Pharmacol Ther, 39(8), pp.350~355 (2001)
- Tsang YC, "High variability in drug pharmacokinetics complicates determination of bioequivalence: experience with verapamil", Pharm Res, 13(6), pp.846~850 (1996)
- Midha KK, "The bioequivalence of highly variable drugs and drug products", Int J Clin Pharmacol Ther, 43(10), pp.485~498 (2005)
- Haidar SH, "Bioequivalence approaches for highly variable drugs and drug products", ~